Janssen Presents New and Updated Results of Imbruvica (ibrutinib) in P-II (CAPTIVATE) Study as Fixed-Duration Combination Regimen for CLL and SLL at EHA 2022
- The P-II (CAPTIVATE) study evaluates I+V in 323 patients with prior untreated CLL & SLL. The results from the 3yr. follow-up showed deep & durable responses, 36mos. PFS & OS (88% & 98% in all patients, 80% & 96% in del(17p)/TP53 mutated & 86% & 97% in unmutated IGHV), CR rate (57%) & consistent for high-risk subgroups, & m-DoR (not reached), 24mos. CR (94%)
- 79% with undetectable uMRD & 78% maintained uMRD @12mos. posttreatment with no new SAEs or secondary malignancies
- The MRD-guided cohort showed a reduction in circulating CLL cell count in patients with uMRD over those not confirmed uMRD, patients with confirmed uMRD had similar cell counts over healthy donors from cycles 16 – 29, with normalization of critical immune cells
Ref: Janssen | Image: Janssen
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.